The stock of Oxford Immunotec Global PLC (NASDAQ:OXFD) hit a new 52-week high and has $15.60 target or 4.00% above today’s $15.00 share price. The 7 months bullish chart indicates low risk for the $339.49M company. The 1-year high was reported on Dec, 1 by Barchart.com. If the $15.60 price target is reached, the company will be worth $13.58M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. The stock increased 1.56% or $0.23 during the last trading session, hitting $15. About 127,854 shares traded hands or 87.56% up from the average. Oxford Immunotec Global PLC (NASDAQ:OXFD) has risen 40.53% since April 28, 2016 and is uptrending. It has outperformed by 34.61% the S&P500.
Analysts await Oxford Immunotec Global PLC (NASDAQ:OXFD) to report earnings on March, 7. They expect $-0.37 EPS, down 27.59% or $0.08 from last year’s $-0.29 per share. After $-0.18 actual EPS reported by Oxford Immunotec Global PLC for the previous quarter, Wall Street now forecasts 105.56% negative EPS growth.
According to Zacks Investment Research, “Oxford Immunotec Global PLC is a medical diagnostics company. It develops new tests for various diseases based on its, patented T cell measurement technology. The company’s first product is the T-SPOT(R). Oxford Immunotec Global PLC is headquartered in Abingdon, the United Kingdom.”
Insitutional Activity: The institutional sentiment increased to 3.15 in Q2 2016. Its up 1.65, from 1.5 in 2016Q1. The ratio improved, as 7 funds sold all Oxford Immunotec Global PLC shares owned while 13 reduced positions. 7 funds bought stakes while 23 increased positions. They now own 17.53 million shares or 3.01% less from 18.07 million shares in 2016Q1.
Moreover, Wasatch Advsr has 0.04% invested in Oxford Immunotec Global PLC (NASDAQ:OXFD) for 274,198 shares. Birchview Capital Lp holds 0.37% or 56,303 shares in its portfolio. Sg Americas Securities Ltd Company holds 12,717 shares or 0% of its portfolio. National Bank & Trust Of America Corp De has 0% invested in the company for 419 shares. Group holds 0% or 12,779 shares in its portfolio. California State Teachers Retirement System last reported 46,546 shares in the company. First Manhattan holds 352,500 shares or 0.02% of its portfolio. Deutsche Bank Ag accumulated 27,817 shares or 0% of the stock. Spark Investment Management Limited holds 0.03% of its portfolio in Oxford Immunotec Global PLC (NASDAQ:OXFD) for 39,200 shares. First Light Asset Mngmt Ltd accumulated 2.92% or 700,849 shares. Bnp Paribas Arbitrage holds 864 shares or 0% of its portfolio. Polar Capital Llp has 1.34 million shares for 0.23% of their US portfolio. Vanguard Gru has invested 0% of its portfolio in Oxford Immunotec Global PLC (NASDAQ:OXFD). Schwab Charles Invest holds 0% of its portfolio in Oxford Immunotec Global PLC (NASDAQ:OXFD) for 29,400 shares. Redmile Grp holds 1.23% or 1.43M shares in its portfolio.
Insider Transactions: Since November 8, 2016, the stock had 0 insider buys, and 2 insider sales for $238,622 net activity. Edwardson Peter sold $68,615 worth of stock. On Tuesday, November 8 the insider SANDBERG RICHARD A sold $170,007.
More news for Oxford Immunotec Global PLC (NASDAQ:OXFD) were recently published by: Metrowestdailynews.com, which released: “Oxford Immunotec Global PLC announces acquisition of Imugen Inc” on June 26, 2016. Seekingalpha.com‘s article titled: “Oxford Immunotec Global PLC (OXFD) CEO Peter Wrighton-Smith on Q3 2016 Results …” and published on November 01, 2016 is yet another important article.
OXFD Company Profile
Oxford Immunotec Global PLC, incorporated on August 16, 2013, is a global, commercial-stage diagnostics firm focused on developing and commercializing tests for the management of immune-regulated conditions. The Company’s T-SPOT technology platform allows it to measure the responses of specific immune cells to inform the diagnosis, prognosis and monitoring of patients with immune-regulated conditions. The Company’s development activities are principally focused on approximately four areas: chronic infections; transplantation; autoimmune and inflammatory disease, and immune-oncology. The Company’s autoimmune and inflammatory disease programs include its SpiroFind assay, targeting Lyme disease; GoutiFind, targeting gout, and Stratokine, targeting efficacy of biologic therapies. Through its early-stage immune-oncology program, it is investigating the use of its T-SPOT technology platform in cancer immunotherapy.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.